Oct. 22, 2012
AstraZeneca and Ironwood Pharma have announced an agreement to co-develop and co-commercialise Ironwood’s linaclotide in China. Linaclotide is the first and only guanylate cyclase-C (GC-C) agonist approved by the US FDA, in August, for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).
In May, Ironwood filed a clinical trial application with the SFDA in China for a Phase III clinical trial to assess the efficacy and safety of linaclotide in adult patients suffering from irritable bowel syndrome with constipation (IBS-C).
AstraZeneca and Ironwood are jointly responsible for strategic oversight of the development and commercialization of linaclotide in China. AstraZeneca will have primary responsibility for the local operational execution.
Under the terms of the collaboration, AstraZeneca will make an upfront payment of $25 million to Ironwood and will share the net profits and losses associated with linaclotide in China. Ironwood will also be eligible for $125 million in additional commercial milestone payments contingent on the achievement of certain sales targets.